Celon Pharma (WAR:CLN) Long-Term Debt: zł0.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:CLN Celon Pharma SA WAR:CLN
48 GF Score
Price zł21.00
GF Value zł23.66
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Long-Term Debt?

Celon Pharma WAR:CLN +7.14% 48 Long-Term Debt is zł0.5 Mil as of Mar. 2026. GuruFocus rates WAR:CLN with a GF Score™ of 48/100 and a GF Value™ of zł23.66 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Celon Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was zł0.5 Mil.

Celon Pharma's quarterly Long-Term Debt stayed the same from Sep. 2025 (zł0.0 Mil) to Dec. 2025 (zł0.0 Mil) but then increased from Dec. 2025 (zł0.0 Mil) to Mar. 2026 (zł0.5 Mil).

Celon Pharma  (WAR:CLN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Celon Pharma Long-Term Debt Related Terms

Celon Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Long-Term Debt Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.53
WAR:CLN
48GF Score
Celon Pharma SA WAR:CLN
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of zł0.5 Mil mean?
Celon Pharma (WAR:CLN) has a Long-Term Debt of zł0.5 Mil as of Mar. 2026.
Is Celon Pharma's Long-Term Debt too high?
Celon Pharma's current Long-Term Debt is zł0.5 Mil. Overall, Celon Pharma has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Long-Term Debt compare to ZTS and UTHR?
Celon Pharma's Long-Term Debt of zł0.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Celon Pharma's current Long-Term Debt is zł0.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Based on GuruFocus' analysis, Celon Pharma (WAR:CLN) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.66, compared to a current price of zł21.00 — trading 11.2% below its estimated fair value. The current Long-Term Debt is zł0.5 Mil. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Celon Pharma (WAR:CLN), the current Long-Term Debt is zł0.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (WAR:CLN) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of zł21.00 is trading 11.2% below its estimated GF Value™ of zł23.66. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for WAR:CLN:

  • Long-Term Debt: zł0.5 Mil
  • GF Value™: zł23.66 vs. price of zł21.00 (11.2% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the WAR:CLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges 8RP:Germany
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for WAR:CLN

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł21.00
Price
zł23.66
GF Value